

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 1 8 2005

Intervascular c/o Ms. Amy Aulwes Health Policy Associates, Inc. 690 Canton Street, Suite 302 Westwood, MA 02090

Re: K042984

InterGard Woven Connector Graft Regulation Number: 21 CFR 870.4210

Regulation Name: Cardiopulmonary Bypass Vascular Catheter, Cannula, and Tubing

Regulatory Class: Class II (two)

Product Code: DWF Dated: January 11, 2005 Received: January 13, 2005

Dear Ms. Aulwes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

## Page 2 - Ms. Amy Aulwes

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Bram D. Zuckerman, M.D.

Duma R. Lochynes

Director

Division of Cardiovascular Devices Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## PRODUCT INDICATIONS FOR USE

(Page 1 of 1)

510(k) <b>[</b>	Number:
-----------------	---------

K042984

Device Name: InterGard Woven Connector

Graft

Indications for Use:

The InterGard Woven Connector Graft is intended for use in arterial perfusion of the aorta, via femoral or axillary artery, for cardiopulmonary bypass when extracorporeal circulation is required for periods up to six (6.0) hours.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use \_\_\_X \_\_\_ OR

OR Over-The-Counter Use \_\_\_\_\_

(Per 21 CFR 801.109)

(Division Sign-Off)

ivision of Cardiovascular Devices

mber\_KC42984